Evidence map›Paper›PMID 41558479›Full record

ArticleCurrent biology : CB2026

Bacterial metabolites induce cell wall remodeling, antifungal resistance, and immune recognition of commensal fungi.

Faith Anderson Davis, Kalpana Singh, Joseph M Krampen, Jackson R Rapala, Jaidyn A Bryant, Michael J McFadden, Kyla S Ost, Shannon E Righi, Marcy J Balunas, Tuo Wang and 1 more

Abstract read
In one paragraph

Article in Current biology : CB, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Faith Anderson DavisDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Kalpana SinghDepartment of Chemistry, Michigan State University, East Lansing, MI 48824, USA.
Joseph M KrampenDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Jackson R RapalaDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Jaidyn A BryantDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Michael J McFaddenDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Kyla S OstDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Shannon E RighiDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Marcy J BalunasDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Tuo WangDepartment of Chemistry, Michigan State University, East Lansing, MI 48824, USA.
Teresa R O'MearaDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: tromeara@umich.edu.

Funding

Molecular Mechanisms of Microbial Pathogenesis Training ProgramT32AI007528 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARRUTHERS, VERNON BRUCE · 1998 to 2024
$6.8M
Discovery of gene function and dissection of network re-wiring in non-model fungiR35GM147894 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Teresa R. OMeara · 2022 to 2026
$2.0M
Dissecting the impact of immune environment on Candida albicans pathogenic potential in the gutDP2AI177927 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Kyla Ost · 2023 to 2026
$2.0M
Revealing the Cell Wall Organization of Fungal Pathogens and Structural Responses to Antifungal Drugs Using Cellular Solid-State NMRR01AI173270 · NIAID · MICHIGAN STATE UNIVERSITY · PI Tuo Wang · 2023 to 2026
$1.5M
Characterization of Interkingdom Synergy between Group B Streptococcus and Candida albicansR21AI188719 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Kelly S Doran, Kyla Ost · 2025 to 2026
$400k
NIAID NIH HHS DP2 AI177927NIAID NIH HHS R01 AI173270NIAID NIH HHS R21 AI188719NIAID NIH HHS T32 AI007528NIGMS NIH HHS R35 GM147894
6 · The paper itself

Abstract

The fungus Candida albicans commensally colonizes mucosal surfaces in healthy individuals but can cause both superficial mucosal and life-threatening disseminated infections. The balance between commensalism and pathogenicity is complex and depends on factors including host and fungal genetic background, the host environment, and fungal interactions with local microbes. The major interaction interface of C. albicans with the host is its multilayered cell wall, which is dynamic and highly responsive to the surrounding environment. Therefore, factors that influence the fungal cell wall will directly impact C. albicans-host interactions. Our work demonstrates that multiple physiologically relevant gastrointestinal bacteria influence fungal cell wall composition during co-culture with C. albicans, including as complex communities derived from the gut. Using Escherichia coli as a model, we show that bacterial-induced fungal cell wall remodeling occurs rapidly and is mediated by secreted bacterial metabolite(s). Fungal mutant analysis revealed that the high osmolarity glycerol (HOG) pathway, which is critical for responding to environmental stresses, has an important role in regulating this cell wall remodeling phenotype through the Sln1 histidine kinase. Importantly, bacterial-mediated fungal cell wall remodeling increases C. albicans resistance to the echinocandins, increases macrophage phagocytic rates, and decreases recognition by human immunoglobulin A (IgA). Overall, this work comprehensively characterizes an interaction between C. albicans and common gastrointestinal bacteria that has important implications for fungal biology and host interactions.

Indexed as

Candida albicansCell WallDrug Resistance, FungalEscherichia coliAnimalsAntifungal AgentsSymbiosisAntifungal AgentsCandidacell wall remodelingfungal-bacterial interactions

Identifiers

PMID41558479
PMCPMC12826303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.